<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362440</url>
  </required_header>
  <id_info>
    <org_study_id>2005P000159</org_study_id>
    <nct_id>NCT00362440</nct_id>
  </id_info>
  <brief_title>Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome</brief_title>
  <official_title>A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with HIV lipodystrophy (fat&#xD;
      wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either&#xD;
      metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by&#xD;
      your fat cells). Our hope is that they will improve sugar and fat metabolism and positively&#xD;
      affect the body fat changes you have noticed while taking HAART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highly active antiretroviral therapy (HAART) induces profound and sustained suppression of&#xD;
      human immunodeficiency virus (HIV) replication, and is thus very effective in reducing&#xD;
      disease-associated morbidity and mortality in this patient population. However, HAART also&#xD;
      results in the development of a lipodystrophic syndrome which is characterized by fat&#xD;
      accumulation, fat wasting, or a combination of both, and similar to congenital forms of&#xD;
      lipodystrophy, is associated with components of the metabolic syndrome, including insulin&#xD;
      resistance (IR), fasting hypertriglyceridemia, and hypercholesterolemia.&#xD;
&#xD;
      Our study is a &quot;proof of concept&quot; study on the treatment of the HAART-induced metabolic&#xD;
      syndrome, which builds upon and represents a direct extension of a study previously funded by&#xD;
      the American Diabetes Association (ADA). If our clinical trial proves that a combination&#xD;
      treatment of leptin and an insulin sensitizer has additive or synergistic effects in&#xD;
      reversing the metabolic abnormalities of HIV positive patients with lipoatrophy, it could&#xD;
      lead to the design of larger multi-center, randomized, placebo-controlled trial(s) aiming at&#xD;
      establishing safety and efficacy of this treatment for the HAART-induced metabolic syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance (HOMA Index)</measure>
    <time_frame>At the end of each 3 month intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol Levels</measure>
    <time_frame>At the end of each 3 month intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition (Fat Mass)</measure>
    <time_frame>At the end of each 3 month intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Leptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leptin replacement therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone or metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diabetes treatment therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leptin</intervention_name>
    <arm_group_label>Leptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone or metformin</intervention_name>
    <arm_group_label>Leptin</arm_group_label>
    <arm_group_label>Pioglitazone or metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Pioglitazone or metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age18 years and above and ability and willingness to give written informed consent&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  At least 6 months of stable cumulative antiretroviral therapy with any available or&#xD;
             investigational anti- retroviral medication (protease inhibitor, nucleoside reverse&#xD;
             transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, nucleotide&#xD;
             reverse transcriptase inhibitor)&#xD;
&#xD;
          -  Lipoatrophy developed after initiating HAART treatment (see criteria below). Leptin&#xD;
             levels should be less than 4 ng/ml.&#xD;
&#xD;
          -  Insulin resistance, impaired fasting glucose, impaired glucose tolerance or type 2&#xD;
             diabetes developed after starting the antiretroviral medications. These categories are&#xD;
             defined, respectively, as fasting insulin level above 15 ÂµIU/ml; fasting serum glucose&#xD;
             value above 100 mg/dl; 2-hour serum glucose level during a 75 gram oral glucose&#xD;
             tolerance test (OGTT) between 140 and 200 mg/dl; and fasting glucose above 126 mg/dl&#xD;
             or random glucose level above 200 mg/dl with presence of the classic symptoms of&#xD;
             diabetes, such as polyuria, polydipsia, ketonuria, and rapid weight loss&#xD;
&#xD;
          -  Hypertriglyceridemia and/or hypercholesterolemia developed after starting the&#xD;
             antiretroviral therapy. These categories are defined as fasting triglycerides greater&#xD;
             than 150 mg/dl and LDL cholesterol greater than 130 mg/dl, respectively&#xD;
&#xD;
          -  Female subjects must have a negative urine pregnancy test before enrollment and must&#xD;
             agree to use a barrier contraception i.e. condoms, diaphragm or IUD, with or without a&#xD;
             hormonal-based method for the duration of the study. Women who are pregnant or become&#xD;
             pregnant during the study and who do not accept some form of contraception will be&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Patients should have history of peripheral fat wasting of the face (e.g. sunken&#xD;
             cheeks), limbs (including prominent veins), and/or buttocks, which developed after the&#xD;
             initiation of HAART therapy&#xD;
&#xD;
          -  Patients should have physical exam findings of a) facial atrophy - sunken cheeks,&#xD;
             sunken temporal regions, and/or prominent temporal veins and b) wasting of fat in&#xD;
             periphery, limbs and/or buttocks (including prominent veins)&#xD;
&#xD;
          -  Patients should have anthropometric measurements suggestive of decreased subcutaneous&#xD;
             fat content: Decreased triceps skinfold thickness (&lt; 4 mm in men and &lt; 8 mm in women)&#xD;
             or Decreased upper arm circumference (&lt; 27.1 cm in men and &lt; 23.3 cm in women) or&#xD;
             Decreased subscapular skinfold thickness (&lt; 7 mm in men and &lt; 7 mm in women) or dual&#xD;
             energy X-ray absorptiometry (DEXA) scanning suggestive of fat depletion: total body&#xD;
             fat &lt; 14% in men and &lt; 22% in women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of impaired glucose metabolism or hyperlipidemia prior to antiretroviral use&#xD;
&#xD;
          -  Triglyceride levels higher than 1500 mg/dl after the 1 month run-in phase or anytime&#xD;
             during the study&#xD;
&#xD;
          -  Abnormal hepatic function: liver function tests higher than twice the upper normal&#xD;
             range&#xD;
&#xD;
          -  Abnormal renal function: creatinine higher than 1.3 mg/dl&#xD;
&#xD;
          -  Any condition/illness that may affect study outcomes such as pregnancy, active&#xD;
             infection except HIV, clinically significant malabsorption/malnutrition, malignancy&#xD;
&#xD;
          -  Any active hormonal disease and/or hormonal treatment that may affect the outcomes of&#xD;
             interest such as clinically overt hypo/hyperthyroidism, hypogonadism,&#xD;
             hypercortisolism, or treatment with steroids or growth hormone (exception: patients&#xD;
             taking testosterone can be included in the trial if they agree to continue the same&#xD;
             dosage for the duration of the trial)&#xD;
&#xD;
          -  Present alcoholism or drug abuse. These conditions will be screened for by a detailed&#xD;
             history and systems review and baseline laboratory analysis with chemistries, CBC, and&#xD;
             hormone levels, and EKG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Mantzoros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006 Jul;91(7):2605-11. Epub 2006 Apr 24.</citation>
    <PMID>16636130</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>February 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV lipodystrophy</keyword>
  <keyword>Leptin</keyword>
  <keyword>Fat wasting</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leptin</title>
          <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone or Metformin</title>
          <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leptin</title>
          <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone or Metformin</title>
          <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="43" upper_limit="57"/>
                    <measurement group_id="B2" value="50" lower_limit="43" upper_limit="57"/>
                    <measurement group_id="B3" value="50" lower_limit="43" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Resistance (HOMA Index)</title>
        <time_frame>At the end of each 3 month intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin</title>
            <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone or Metformin</title>
            <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance (HOMA Index)</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.5"/>
                    <measurement group_id="O2" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol Levels</title>
        <time_frame>At the end of each 3 month intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin</title>
            <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone or Metformin</title>
            <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol Levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="13"/>
                    <measurement group_id="O2" value="183" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition (Fat Mass)</title>
        <time_frame>At the end of each 3 month intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leptin</title>
            <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone or Metformin</title>
            <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition (Fat Mass)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="1.7"/>
                    <measurement group_id="O2" value="13.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Leptin</title>
          <description>Leptin replacement therapy&#xD;
Leptin+pioglitazone</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone or Metformin</title>
          <description>Diabetes treatment therapy&#xD;
Pioglitazone+placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christos Mantzoros</name_or_title>
      <organization>BIDMC</organization>
      <phone>617-667-8630</phone>
      <email>cmantzor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

